Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Significant Decrease in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 281,800 shares, a decrease of 40.4% from the July 15th total of 472,500 shares. Based on an average daily volume of 4,650,000 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AEMD. HC Wainwright reduced their price objective on Aethlon Medical from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, June 24th. StockNews.com began coverage on Aethlon Medical in a research report on Sunday, June 23rd. They issued a “sell” rating for the company.

Aethlon Medical Stock Performance

Shares of AEMD traded up $0.09 during mid-day trading on Friday, hitting $0.41. The company’s stock had a trading volume of 4,190,022 shares, compared to its average volume of 1,988,189. Aethlon Medical has a one year low of $0.24 and a one year high of $3.20. The firm has a market capitalization of $5.64 million, a PE ratio of -0.08 and a beta of 1.65. The stock’s 50-day moving average is $0.45 and its two-hundred day moving average is $1.05.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings data on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.10. During the same period in the prior year, the firm earned ($1.30) earnings per share. Analysts expect that Aethlon Medical will post -1.13 EPS for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.